Feature | July 07, 2010| Dave Fornell

Thrombectomy to Treat Pulmonary Embolism

Pulmonary embolism (PE) is generally treated with blood thinners, but a more aggressive treatment may be required for massive PE in hemodynamically compromised patients, said Ali Amin, M.D., a vascular surgeon at The Read Hospital and Medical Center in Reading, Pa. In these unstable patients with respiratory distress and near death, he said the AngioJet could be used off-label as an emergency treatment.

“You can use AngioJet in these patients to remove the clot and save their lives,” Amin said. “In these situations, you are not looking to get a perfect picture, you just want to remove enough of the clot to improve the blood pressure and the oxygen saturation.”

Once most of thrombus is removed to improve these factors, he said it is best to stop and continue treating the patient medically. “Your goal is very limited. Once you get oxygen saturation up, your job is done,” he explained.

Peter Soukas, M.D., director of vascular medicine and assistant professor of medicine, Tufts University School of Medicine, St. Elizabeth’s Medical Center, Boston, urges caution with the use of AngioJet in this application. He said people can get very sick if it is used to break up clots in the pulmonary artery, due to the possibility of distal embolization, resulting in acute right ventricular failure. The lysis of red blood cells results in the sudden release of large amounts of adenosine, which may lead to profound bradycardia. For this reason, a temporary pacemaker wire is often used when treating large proximal PE with the AngioJet.

Ekos for Pulmonary Embolism

Ekos plans a randomized clinical trial, ULTIMA (the ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism) to show the clinical benefit of an endovascular device to treat acute submassive pulmonary embolism in comparison to anticoagulation therapy alone. Enrollment is expected to commence in 2010 and be completed by the beginning of 2011.

Pulmonary embolism occurs at a rate of approximately 24 per 100,000 people and accounts for up 150,000 to 500,000 deaths per year in the United States and Europe and affects more than 1.6 million patients annually. Serious pulmonary emboli interfere with the heart’s ability to pump blood into the lungs for oxygenation, causing acute strain of the right side of the heart and potentially causing death.
Current treatments typically involve aggressive anticoagulation or intravenous delivery of clot-dissolving, thrombolytic agents.

Related Content

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Technology | Pulmonary Embolism| March 01, 2017
March 1, 2017 — BTG plc announced U.S.
global thrombectomy devices market, Allied Market Research report, 2022
News | Thrombectomy Devices| January 05, 2017
January 5, 2017 — A new report published by Allied Market Research forecasts that the global...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Penumbra System, ACE68 Reperfusion Catheter, thrombectomy device, SNIS 2016, acute ischemic stroke patients
Technology | Thrombectomy Devices| July 27, 2016
July 27, 2016 — Penumbra Inc. announced U.S.
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
Pulmonary embolism, toshiba

A pulmonary embolism visualized on a CTA scan using SureSubtraction software on a Toshiba Aquilion One Vision CT scanner. 

Feature | Pulmonary Embolism| March 28, 2016 | Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.
Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians.
SITS Open trial, mechanical thrombectomy devices. pREset, stroke treatment
News | Thrombectomy Devices| March 08, 2016
March 8, 2016 — phenox GmbH announced participation in the SITS Open clinical trial, where pREset and pREset LITE ...
Overlay Init